May 20, 2019
Fuji Pharma President Eiji Takemasa Fuji Pharma expects that some of the investigational biosimilars currently under development by its Icelandic partner will be filed in Japan by 2021, President Eiji Takemasa, explained at an earnings briefing on May 17. Fuji...read more